UGC Approved Journal no 63975

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 9 | Issue 1 | January 2022

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 8 Issue 7
July-2021
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR2107293


Registration ID:
311587

Page Number

c192-c199

Share This Article


Jetir RMS

Title

Development of Monoclonal antibody against Human Epidermal Growth Factor Receptor 2 a marker of belligerent Breast Cancer

Abstract

Human Epidermal Growth Factor Receptor 2 (HER-2) proteins are receptors on breast cells which help to control how a healthy breast cell grows, divides, and repairs itself. In breast cancers, the HER2 gene doesn’t work correctly and makes too many copies of itself and signals breast cells to make too many HER2 receptors. Over-expression of this oncogene plays an important role in the development and progression of certain aggressive types of breast cancer by making breast cells to grow and divide in an uncontrolled way. HER2 has become an important biomarker and target of therapy for breast cancer patients. Its epitope is localized in the extracellular domain and consists of an extracellular ligand-binding domain that is connected to a large intracellular domain by a single transmembrane sequence. In this study we have developed a monoclonal antibody against HER-2 and validated it by ELISA, Western Blotting and Immunohistochemistry. It recognizes a protein of 185kDa, which is identified as c-erbB-2/HER-2/neu.. C-erbB-2/HER-2 is a member of the EGFR family.. Receptors of this family are. c-erbB-2/HER-2 protein is over-expressed in a variety of carcinomas especially those of breast and ovary. The developed monoclonal antibody was used to observe the expression level of HER2 in human breast cancer tissues by Immunohistochemistry. The antibody staining was seen on the membranes of the breast cancer cells which is specific and shows minimal cross-reaction with other members of the EGFR-family. This antibody can be used in the diagnosis of HER-2 positive breast cancers.

Key Words

Human Epidermal Growth Factor Receptor 2 (HER-2); Breast cancer marker; Immunohistochemistry

Cite This Article

"Development of Monoclonal antibody against Human Epidermal Growth Factor Receptor 2 a marker of belligerent Breast Cancer", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.8, Issue 7, page no.c192-c199, July-2021, Available :http://www.jetir.org/papers/JETIR2107293.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"Development of Monoclonal antibody against Human Epidermal Growth Factor Receptor 2 a marker of belligerent Breast Cancer", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.8, Issue 7, page no. ppc192-c199, July-2021, Available at : http://www.jetir.org/papers/JETIR2107293.pdf

Publication Details

Published Paper ID: JETIR2107293
Registration ID: 311587
Published In: Volume 8 | Issue 7 | Year July-2021
DOI (Digital Object Identifier):
Page No: c192-c199
Country: Bhubaneswar, Odisha, India .
Area: Medical Science
ISSN Number: 2349-5162


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

000201

Print This Page

Current Call For Paper

Jetir RMS